Liquid Biopsy in EGFR-Mutated Advanced NSCLC from T790M to MET Amplification: Clinical Implications and Possibilities in the Resistance Setting

被引：0

作者：

Della Gravara, Luigi ^{[1
]}

Battiloro, Ciro ^{[2
]}

Avellino, Aniello ^{[2
]}

Caputo, Francesca ^{[3
]}

D'Aniello, Carmine ^{[3
]}

Rocco, Danilo ^{[2
]}

机构：

[1] Univ Campania Luigi Vanvitelli, Dept Precis Med, I-80138 Naples, Italy

[2] AORN Colli Monaldi, Dept Pulm Oncol, I-80131 Naples, Italy

[3] AORN Colli Monaldi, Dept Med Oncol, I-80131 Naples, Italy

来源：

JOURNAL OF MOLECULAR PATHOLOGY | 2023年 / 4卷 / 02期

关键词：

NSCLC; EGFR; MET; osimertinib; liquid biopsy; NGS; cfDNA; ctDNA; CELL LUNG-CANCER; TREATMENT ALGORITHM; OSIMERTINIB; THERAPY; C797S; 1ST;

D O I：

10.3390/jmp4020009

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

According to the ESMO and ASCO clinical guidelines, the main role of liquid biopsy in EGFR+ advanced NSCLC patients is represented by T790M detection after erlotinib/gefitinib/afatinib progression. However, the general international expert consensus regards osimertinib as the preferred upfront treatment in this setting; therefore, this role has been scaled back in recent years. As of today, liquid biopsy has no ASCO or ESMO recommendation following first-line osimertinib; in the same vein, no targeted therapy has received ASCO or ESMO recommendation following post upfront Osimertinib progression. However, this standard could change in the near future. Therefore, adopting a clinical point of view, this paper aims to provide a comprehensive review on the previous, the current and the possible future role of liquid biopsy in the framework of the diagnostic-therapeutic algorithm of EGFR+ advanced NSCLC.

引用

页码：81 / 88

页数：8

共 59 条

[51] Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
Soria, J. -C.
Ohe, Y.
Vansteenkiste, J.
Reungwetwattana, T.
Chewaskulyong, B.
Lee, K. H.
Dechaphunkul, A.
Imamura, F.
Nogami, N.
Kurata, T.
Okamoto, I.
Zhou, C.
Cho, B. C.
Cheng, Y.
Cho, E. K.
Voon, P. J.
Planchard, D.
Su, W. -C.
Gray, J. E.
Lee, S. -M.
Hodge, R.
Marotti, M.
Rukazenkov, Y.
Ramalingam, S. S.
Boyer, Michael
Lee, Chee
Hughes, Brett
O'Byrne, Kenneth
Briggs, Peter
Milward, Michael
John, Thomas
Demedts, Ingel
Vansteenkiste, Johan
Bustin, Frederique
Barrios, Carlos Henrique
Timcheva, Constanta
Butts, Charles
Goss, Glenwood
Juergens, Rosalyn
Leighl, Natasha
Cheng, Susanna
Burkes, Ronald
Zhou, Caicun
Zhang, Helong
Shu, Yongqian
Cheng, Ying
Zhou, Qing
Li, Wei
Feng, Guosheng
He, Yong
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02) : 113 - 125
[52] Tagrisso plus, AstraZeneca.com
[53] Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases
Tran, Thang N.
Selinger, Christina I.
Kohonen-Corish, Maija R. J.
McCaughan, Brian
Kennedy, Catherine
O'Toole, Sandra A.
Cooper, Wendy A.
[J]. CLINICAL LUNG CANCER, 2016, 17 (01) : 30 - +
[54] Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance
Wang, Zhen
Yang, Jin-Ji
Huang, Jie
Ye, Jun-Yi
Zhang, Xu-Chao
Tu, Hai-Yan
Han-Zhang, Han
Wu, Yi-Long
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : 1723 - 1727
[55] Phase 1b/2 study of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated non-small cell lung cancer who received prior therapy: Final overall survival and safety.
Wu, Yi-Long
Zhang, Li
Kim, Dong-Wan
Liu, Xiaoqing
Lee, Dae Ho
Yang, James Chih-Hsin
Ahn, Myung-Ju
Vansteenkiste, Johan F.
Su, Wu-Chou
Felip, Enriqueta
Carbini, Mariana
Glaser, Sabine
Tanriverdi, Oezlem
Chassot-Agostinho, Andrea
Tan, Daniel Shao-Weng
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[56] Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
Wu, Yi-Long
Cheng, Ying
Zhou, Jianying
Lu, Shun
Zhang, Yiping
Zhao, Jun
Kim, Dong-Wan
Soo, Ross Andrew
Kim, Sang-We
Pan, Hongming
Chen, Yuh-Min
Chian, Chih-Feng
Liu, Xiaoqing
Tan, Daniel Shao Weng
Bruns, Rolf
Straub, Josef
Johne, Andreas
Scheele, Jurgen
Park, Keunchil
Yang, James Chih-Hsin
[J]. LANCET RESPIRATORY MEDICINE, 2020, 8 (11) : 1132 - 1143
[57] Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
Wu, Yi-Long
Zhang, Li
Kim, Dong-Wan
Liu, Xiaoqing
Lee, Dae Ho
Yang, James Chih-Hsin
Ahn, Myung-Ju
Vansteenkiste, Johan F.
Su, Wu-Chou
Felip, Enriqueta
Chia, Vincent
Glaser, Sabine
Pultar, Philippe
Zhao, Sylvia
Peng, Bin
Akimov, Mikhail
Tan, Daniel S. W.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (31) : 3101 - +
[58] A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients withEGFR-mutated,MET-amplified advanced non-small-cell lung cancer
Yang, Jin-Ji
Fang, Jian
Shu, Yong-Qian
Chang, Jian-Hua
Chen, Gong-Yan
He, Jian Xing
Li, Wei
Liu, Xiao-Qing
Yang, Nong
Zhou, Caicun
Huang, Jian An
Frigault, Melanie M.
Hartmaier, Ryan
Ahmed, Ghada F.
Egile, Coumaran
Morgan, Shethah
Verheijen, Remy B.
Mellemgaard, Anders
Yang, Liu
Wu, Yi-Long
[J]. INVESTIGATIONAL NEW DRUGS, 2021, 39 (02) : 477 - 487
[59] ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy
Yu, H.
Goldberg, S.
Le, X.
Piotrowska, Z.
Smith, P.
Mensi, I.
Kirova, B.
Chmielecki, J.
Li-Sucholeicki, X.
Szekeres, P.
Doughton, G.
Patel, G.
Jewsbury, P.
Riess, J.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S647 - S647

← 1 2 3 4 5 6 →